Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Halozyme Therapeutics's enterprise value was $13.58B on Nov 11, 2026, against $9.48B a year earlier. Over the last 5 years it ranged from $4.15B to $16.91B, with a median of $7.74B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $13.58B | +50.9% |
| 2025 | Dec 31, 2025 | $9.00B | +21.1% |
| 2024 | Dec 31, 2024 | $7.43B | +21.7% |
| 2023 | Dec 29, 2023 | $6.11B | -31.6% |
| 2022 | Dec 30, 2022 | $8.93B | +80.8% |
| 2021 | Dec 31, 2021 | $4.94B | -9.1% |
| 2020 | Dec 31, 2020 | $5.43B | +109.7% |
| 2019 | Dec 31, 2019 | $2.59B | +20.7% |
| 2018 | Dec 31, 2018 | $2.15B | -22.7% |
| 2017 | Dec 29, 2017 | $2.78B | +126.0% |
| 2016 | Dec 30, 2016 | $1.23B | -43.0% |
| 2015 | Dec 31, 2015 | $2.16B | +83.7% |
| 2014 | Dec 31, 2014 | $1.18B | -30.8% |
| 2013 | Dec 31, 2013 | $1.70B | +153.9% |
| 2012 | Dec 31, 2012 | $668.55M | -27.3% |
| 2011 | Dec 30, 2011 | $919.36M | – |
See a number that looks wrong?